Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.
Randomized, double-blind, placebo-controlled, dose-escalation Phase I safety study of inhaled N-IP-00001, to determine tolerability and safety in healthy volunteers.
100 Clinical Results associated with NeoTrials Pty Ltd
0 Patents (Medical) associated with NeoTrials Pty Ltd
100 Deals associated with NeoTrials Pty Ltd
100 Translational Medicine associated with NeoTrials Pty Ltd